What's new? Log in Free sign up

XOMA Royalty (XOMA)

Company Profile

Company profile

Ticker

XOMA, XOMAO, XOMAP

Exchange

Website

CEO

Owen P. Hughes Jr.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

XOMA Corp, XOMA CORP /DE/, XOMA LTD /DE/

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

XOMA Technology Ltd. • XOMA (US) LLC • XOMA UK Limited • XRL 1 LLC • Kinnate Biopharma Inc. • Pulmokine, Inc. ...

IRS number

942756657

XOMA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$72.67

Low target

$45.00

High target

$97.00

HC Wainwright & Co.

Leerink Partners

LUCID CAPITAL MARKETS

Latest filings (excl ownership)

View all

XOMA Royalty Announces CFO Transition

Third party tender offer statement (amended)

Regulation FD Disclosure

Third party tender offer statement

Information about tender offer

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Completion of Acquisition or Disposition of Assets

Third party tender offer statement (amended)

Third party tender offer statement (amended)

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results

Latest ownership filings

View all

Jeffrey Trigilio

Jeffrey Trigilio

THOMAS M. BURNS

Maricel Perea Montano

Maricel Perea Montano

Maricel Perea Montano

Maricel Perea Montano

Financial summary

Financial statements Chart XOMA financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	130.55 mm	130.55 mm	130.55 mm	130.55 mm	130.55 mm	130.55 mm
Cash burn (monthly)	(no burn)	1.36 mm	(no burn)	(no burn)	98.67 k	(no burn)
Cash used (since last report)	n/a	4.95 mm	n/a	n/a	360.65 k	n/a
Cash remaining	n/a	125.60 mm	n/a	n/a	130.19 mm	n/a
Runway (months of cash)	n/a	92.7	n/a	n/a	1319.5	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

XOMA institutional ownership history Ownership history

96.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	67	69	-2.9%
Opened positions	5	50	-90.0%
Closed positions	7	2	+250.0%
Increased positions	22	4	+450.0%
Reduced positions	14	7	+100.0%

13F shares	Current	Prev Q	Change
Total value	201.35 bn	199.19 bn	+1.1%
Total shares	11.99 mm	11.87 mm	+1.0%
Total puts	2.60 k	1.60 k	+62.5%
Total calls	1.20 k	100.00	+1100.0%
Total put/call ratio	2.2	16.0	-86.5%

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	3.63 mm	$75.44 mm	0.0%
BVF	3.63 mm	$95.49 bn	0.0%
FMR	1.09 mm	$28.65 bn	-1.1%
NVS Novartis	539.13 k	$8.76 mm	0.0%
BLK BlackRock	538.92 k	$14.16 bn	+0.6%
Vanguard	463.84 k	$12.19 bn	+9.8%
MS Morgan Stanley	317.32 k	$8.34 bn	+73.5%
Opaleye Management	250.00 k	$6.57 bn	0.0%
Geode Capital Management	182.19 k	$4.79 bn	-0.3%
Woodline Partners	156.27 k	$4.11 bn	+63.9%

Largest transactions	Shares	Bought/sold	Change
MS Morgan Stanley	317.32 k	+134.47 k	+73.5%
Stonepine Capital Management	125.70 k	-69.40 k	-35.6%
Woodline Partners	156.27 k	+60.93 k	+63.9%
Vanguard	463.84 k	+41.45 k	+9.8%
Acuitas Investments	60.70 k	-27.35 k	-31.1%
Ellsworth Advisors	0.00	-19.48 k	EXIT
Millennium Management	0.00	-15.29 k	EXIT
Marshall Wace	0.00	-14.44 k	EXIT
FMR	1.09 mm	-12.35 k	-1.1%
JPM JPMorgan Chase & Co.	12.09 k	+8.52 k	+238.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XOMA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Jan 26	Jeffrey Trigilio	Performance Stock Units Common Stock	Grant	Acquire A	No	No	0	30,000	0.00	30,000
4 Dec 25	Owen Hughes	Depositary Shares - 8.375% B Cumulative Stock	Buy	Acquire P	No	No	25.05	100,000	2.51 mm	102,000
22 Sep 25	Burns Thomas M.	Common Stock	Sell	Dispose S	No	No	36.81	15	552.15	30,079
22 Sep 25	Burns Thomas M.	Common Stock	Sell	Dispose S	No	No	36.93	15	553.95	30,094
22 Sep 25	Burns Thomas M.	Common Stock	Sell	Dispose S	No	No	35.98	4,300	154.71 k	30,109
19 Sep 25	Burns Thomas M.	Common Stock	Option exercise	Acquire M	No	No	0	11,846	0.00	34,409
19 Sep 25	Burns Thomas M.	Performance Stock Units Common Stock	Option exercise	Dispose M	No	No	0	11,846	0.00	44,208
19 Sep 25	Maricel Perea Montano	Common Stock	Option exercise	Acquire M	No	No	0	3,033	0.00	12,134
19 Sep 25	Maricel Perea Montano	Performance Stock Units Common Stock	Option exercise	Dispose M	No	No	0	3,033	0.00	11,316

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction

Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reducedXOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of

XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger

XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of

HC Wainwright & Co. Maintains Buy on XOMA Royalty, Lowers Price Target to $97

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:XOMA) with a Buy and lowers the price target from $104 to $97.

Why Is XOMA Royalty Stock Sinking Thursday?

Leerink Partners Maintains Outperform on XOMA Royalty, Lowers Price Target to $45

Press releases

From Benzinga Pro

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ:XOMA). Such investors are advised to contact

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ:XOMA). Such investors are advised to

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ:XOMA). Such investors are advised to contact

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

XOMA Royalty Declares Quarterly Preferred Stock Dividends

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.